Amended Claims

Claims 1-7 (canceled).

8. **(currently amended)** A compound**; an isomer of the compound, enantiomer of the compound, tautomer of the compound, racemate of the compound, or polymorph of the compound; or a pharmaceutically-acceptable salt of the compound, isomer, enantiomer, tautomer, or racemate, wherein: [[of]]**

the **compound corresponds in structure to** Formula I**:**



I;

~~**wherein**~~

Z_1 is selected from the group consisting of CH_2, O, CH_2O, NH, S, SO, $CH(OH)$, and SO_2;

Z_2 is a 1-5 carbon linker optionally containing one or more ~~**heteroatom**~~ **heteroatoms** selected from the group consisting of O, S, and N; **[[or]]**

Z_1-Z_2 optionally **further contains** ~~**contain**~~ a carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, or acyl**;** ~~**group; wherein**~~

the carbon and nitrogen atoms of Z_1-Z_2 are optionally substituted by a substituent selected from the group consisting of alkyl, alkoxy, ~~**thioalkyl**~~ **alkylthio**, alkylsulfone, aryl, alkoxyalkyl, alkylamino, heteroaryl, hydroxyl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

each n is ~~**an integer**~~ selected from the group consisting of zero, 1, and 2;

R^c is selected from the group consisting of hydrogen, alkyl, halogen, hydroxyl, nitro, alkoxy, amino, haloalkyl, aryl, heteroaryl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, ~~thioalkyl~~ **alkylthio**, alkylamino, arylamino, alkylsulfonylamino, acyl, acylamino, sulfonyl, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, alkynylalkyl, carboxy, alkoxycarbonyl, carboxamido, cyano, and $-(CH_2)_n-COR$; ~~wherein n is an integer selected from the group consisting of zero, 1 and 2, and~~

R is selected from the group consisting of hydroxyl, alkoxy, alkyl, and amino;

X is selected from the group consisting of [[-O-]] **O**, CO, SO_2, NR^m, and $(CHR^p)_n$; ~~wherein~~

R^p and R^m are H or alkyl; ~~, n is an integer selected from the group consisting of zero, 1 and 2; R^b is X_3-R^h wherein~~

X_3 is selected from the group consisting of O, S, and NR^j; ~~wherein~~

R^h and R^j are independently selected from the group consisting of H, alkyl, acyl, aryl, aralkyl, and alkoxyalkyl; and

~~the ring A-B~~  ~~is~~  ~~; and A1~~

A^1 is selected from the group consisting of:

































Page 4 of 30

























Page 5 of 30

























Page 6 of 30

























Page 7 of 30

































[[,]]



















[[,]]













































[[,]]











[[,]]











































































































Page 15 of 30









































, and



~~and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates or polymorphs thereof, wherein m is an integer selected from the group consisting of 1 and 2; B^1 is selected from the group consisting of CH_2, O, CO, S, CF_2, SO_2 and NR^6; B^2 is selected from the group consisting of N and CH; B^3 is selected from the group consisting of N and CH; B^4 is selected from the group consisting of NH, O and S; B^5 is selected from the group consisting of NH, O and S; B^6 is selected from the group consisting of N and CH; B^7 is~~

~~selected from the group consisting of CH_2, O, CO, S, CF_2, SO_2 and NR^e; R^{79} is selected from the group consisting of OR^e, OH, H and Me; R^{80} is selected from the group consisting of H and Me; R^{81} is selected from the group consisting of OR^e, OH and Me; X^7 is selected from the group consisting of O, S, NR^e, SO_2 and CF_2; X^8 is selected from the group consisting of CH_2, O, S, NR^e, SO_2 and $CONR^e$; and R^e is selected from the group consisting of H, alkyl and amino~~.

9. **(currently amended)** A compound, **isomer, enantiomer, tautomer, racemate, polymorph, or salt** according to claim 8, wherein said compound is 1,2,3,4-tetrahydro-1-oxo-[6-[3-(2-tetrahydropyrimidinyl)amino]-propoxy]-2-isoquinolineacetic acid ~~, and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates or polymorphs thereof~~.

10. **(currently amended)** A pharmaceutical composition, **wherein the composition comprises:** ~~comprising a therapeutically effective amount of~~

a compound, **isomer, enantiomer, tautomer, racemate, polymorph, or salt** of claim 8 **in an amount that is effective to inhibit or antagonize $\alpha_v\beta_3$ or $\alpha_v\beta_5$;** and

a pharmaceutically acceptable carrier.

11. **(currently amended)** A method for treating a condition mediated by the $\alpha_v\beta_3$ integrin **in a mammal, wherein:**

the condition is selected from the group consisting of tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy, and arthritis; **and** ~~in a mammal in need of such treatment comprising~~

the method comprises administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound, **isomer, enantiomer, tautomer, racemate, polymorph, or salt** of claim 8.

Claim 12. (canceled).

13. **(currently amended)** A method for treating a condition mediated by the $\alpha_v\beta_5$ integrin **in a mammal, wherein:**

the condition is selected from the group consisting of tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy, and arthritis**; and** ~~**in a mammal in need of such treatment comprising**~~

the method comprises administering an effective $\alpha_v\beta_5$ inhibiting amount of a compound**, isomer, enantiomer, tautomer, racemate, polymorph, or salt** of claim 8.

Claim 14. (canceled).

15. **(currently amended)** A method of treating neoplasia in a patient in need thereof**, wherein the method comprises** ~~**comprising**~~ administering a compound**, isomer, enantiomer, tautomer, racemate, polymorph, or salt** of claim 8 in combination with a chemotherapeutic agent.

Claim 16. (canceled).